| abstract |
The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-a 2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as 0 adrenergin receptor agonists, p adrenergin receptor antagonists, and/or glycemic control agents. |